Purpose: The purpose of the study was to describe the development and feasibility of implementing the DM-BOOST program in support of an established diabetes self-management education and support (DSMES) program.
Methods: A patient panel of 4 adults with type 2 diabetes (T2DM) codesigned DM-BOOST. DM-BOOST is a patient-focused program that includes peer-written text messages about diabetes self-management behaviors and digital health training to improve patient portal use and initiate goal setting prior to a scheduled DSMES appointment. Adults with T2DM and A1C ≥8.0% participated in a 6-month feasibility pilot. Participants were randomly assigned (1:1) to receive either DM-BOOST or usual care. Outcomes included DSMES engagement (scheduled and attended DSMES appointments) and changes in diabetes self-efficacy and treatment satisfaction.
Results: Pilot participants (n = 60) were 60.0% female with mean age 45.5 years (SD 8.3) and A1C 10.1% (SD 1.8%). All DM-BOOST participants (30/30, 100%) had DSMES appointments scheduled compared to 86.7% of usual care (26/30). DM-BOOST participants had fewer DSMES appointment no-shows/cancellations (3/30, 10%) compared to usual care (10/26, 35%). There was greater improvement in diabetes self-efficacy in the DM-BOOST group compared to usual care and no difference in treatment satisfaction.
Conclusions: DM-BOOST, leveraging peer-written text messaging and digital health training, increased DSMES engagement. Implementation of DM-BOOST was determined to be feasible, with several system-level barriers identified, including obtaining provider referrals and scheduling appointments. An effectiveness trial of DM-BOOST is needed to evaluate the impact on clinical outcomes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/26350106241285829 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Medication continuity of older adults at discharge: implementation of a personalized prescription plan versus usual care].
Geriatr Psychol Neuropsychiatr Vieil
December 2024
Research Department, Biostatistics, Lille Catholic Hospitals, Lille, France.
The personalized prescription plan (PPP) summarizes the changes made to a patient's prescription on discharge from hospital. The aim of the present study was to evaluate 30-day medication continuity in older patients whose PPP was implemented at hospital discharge. Prospective randomized controlled trial including people aged at least 75 discharged from an acute geriatric unit.
View Article and Find Full Text PDFEffects of the Stanford Chronic Conditions Model on Behavioral and Clinical Indicators in Saudi Arabia: A Prospective Quasi-Experimental Study.
J Multidiscip Healthc
January 2025
Medical Surgical Department, College of Nursing, King Saud University, Riyadh, Saudi Arabia.
Purpose: This study aimed to evaluate the 6-month impact of the Chronic Disease Self-Management Program based on the Stanford chronic condition model on behavioral and clinical indicators in individuals with chronic illnesses.
Patients And Methods: This prospective, quasi-experimental study was conducted in primary healthcare centers located in Riyadh, Saudi Arabia. A total of 110 adults aged 18 years or older, living with at least one chronic disease, and receiving treatment at a primary healthcare center were included.
Remote patient monitoring in heart failure: A comprehensive meta-analysis of effective programme components for hospitalization and mortality reduction.
Eur J Heart Fail
January 2025
Department of Cardiology, Máxima Medical Centre, Veldhoven, The Netherlands.
Aims: Methods of non-invasive remote patient monitoring (RPM) for heart failure (HF) remain diverse. Understanding factors that influence the effectiveness of RPM on HF-related and all-cause hospitalizations, mortality, and emergency department visits is crucial for developing successful RPM interventions. This meta-analysis aims to synthesize and compare existing literature on RPM components that impact HF-related and all-cause hospitalizations, mortality and emergency department visits in HF patients.
View Article and Find Full Text PDFMapping the effectiveness and risks of GLP-1 receptor agonists.
Nat Med
January 2025
Clinical Epidemiology Center, Research and Development Service, VA St. Louis Health Care System, St. Louis, MO, USA.
Glucagon-like peptide 1 receptor agonists (GLP-1RAs) are increasingly being used to treat diabetes and obesity. However, their effectiveness and risks have not yet been systematically evaluated in a comprehensive set of possible health outcomes. Here, we used the US Department of Veterans Affairs databases to build a cohort of people with diabetes who initiated GLP-1RA (n = 215,970) and compared them to those who initiated sulfonylureas (n = 159,465), dipeptidyl peptidase 4 (DPP4) inhibitors (n = 117,989) or sodium-glucose cotransporter-2 (SGLT2) inhibitors (n = 258,614), a control group composed of an equal proportion of individuals initiating sulfonylureas, DPP4 inhibitors and SGLT2 inhibitors (n = 536,068), and a control group of 1,203,097 individuals who continued use of non-GLP-1RA antihyperglycemics (usual care).
View Article and Find Full Text PDFDepRescribing inapprOpriate Proton Pump InhibiTors (DROPIT): study protocol of a cluster-randomised controlled trial in Swiss primary care.
BMJ Open
January 2025
Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland
Objectives: Proton pump inhibitors (PPIs) are widely prescribed medications and commonly used for the treatment of gastric acid-related disorders. Nevertheless, PPIs are often overused leading to potential adverse effects and unnecessary healthcare costs. Deprescribing strategies have emerged to safely reduce or substitute inappropriate PPIs and optimise patient care in an evidence-based manner.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!